Efficacy, Safety, and Tolerability of a GLP-1/GCG Dual Receptor Agonist in Type 2 Diabetes Patients With Cognitive Dysfunction: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Trial
Latest Information Update: 01 Aug 2025
At a glance
- Drugs Mazdutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms LIGHT-COG
Most Recent Events
- 01 Aug 2025 New trial record